Bioventix是一家專注研發(fā)用于免疫診斷、臨床診斷和藥物濫用檢測(cè)領(lǐng)域的高親和力羊單克隆抗體（SMAs）的生物技術(shù)公司。Bioventix公司生產(chǎn)的高親和力抗體優(yōu)于常規(guī)嚙齒動(dòng)物單克隆抗體，其中靶標(biāo)存在于低濃度，或目標(biāo)是半抗原或小分子。高親和力SMAs的使用還賦予改善檢測(cè)的靈敏度和精確度。Bioventix公司已成功開發(fā)出SMAs目標(biāo)，傳統(tǒng)的單克隆或多克隆抗體未能產(chǎn)生一個(gè)合適的試劑。

BACKGROUND & HISTORY

Bioventix was founded in 2003 as a biotechnology company specialising in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. However, the antibody technology laboratory and some of the staff have been based at the same location in Farnham, Surrey, UK since the early 1990s.

Focusing on the areas of clinical diagnostics and drugs of abuse testing the Company’s strategy is to identify new or existing commercial assays for which there is or may be a need for improved antibodies. We aim to provide clients with high quality SMAs that address the shortcomings of other antibodies. The high-affinity antibodies created at Bioventix have advantages over conventional rodent monoclonal antibodies where the target is present at low concentration, or where the target is a short peptide sequence or where the target is a small molecule or drug. In many assay formats, the use of high-affinity SMAs confers improved assay sensitivity and precision.

Bioventix has successfully developed SMAs to targets where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent and supplies antibodies to almost all of the global multinational immunodiagnostics companies.

The company was admitted to trade on the Alternative Investment Market (AIM) in April 2014. Since then the company has excelled in financial and share price performance.